Industry Watch [to 29 October 2016]
:: PaxVax’s Vaxchora™ Now Available as the Only U.S. Approved Vaccine for Protection Against Cholera
REDWOOD CITY, Calif., Oct. 24, 2016 /PRNewswire/ — PaxVax, Inc. announced that Vaxchora™ is now available in the United States (U.S.) as the country’s only vaccine for protection against cholera, a highly contagious intestinal diarrheal infection that can cause death in less than 24 hours if left untreated.1…
Vaxchora, a single-dose vaccine, was approved by the U.S. Food and Drug Administration (FDA) in June 2016 for use in U.S. adults traveling to cholera-affected areas as an active immunization against disease caused by Vibrio cholerae serogroup O1. Also in June 2016, The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend Vaxchora for travelers to areas of active cholera transmission…
“We are excited that Vaxchora is now available to Americans traveling to areas affected by cholera. This is particularly timely in light of the number of U.S. citizens, including members of the U.S. military, joining relief efforts in Haiti,” said Nima Farzan, Chief Executive Officer and President of PaxVax. “Vaccinating those traveling to cholera-affected areas can help mitigate its spread and can help protect them against the disease,” said Farzan.
PaxVax has also made a donation to international medical organization Partners In Health (http://www.pih.org) to support the relief efforts in Haiti with specific focus on cholera prevention and treatment.